Atyr Pharma WKN: A2PM86 ISIN: US0021202025 Forum: Aktien User: Spottford

4,82€

Rechtzeitig bedeutet? 1€?

Klingt nicht gut

Über die DiBa bin ich noch rechtzeitig rausgekommen. Sehr schade ...

Kurs aktuell bei 1$ halted

GG

https://investors.atyrpharma.com/news-releases/news-release-details/atyr-pharma-announces-topline-results-phase-3-efzo-fittm-study

Jetzt geht’s los, HALTED

Wird halt volatil bis dahin. Man hätte auch am Freitag denken können leak und alle kaufen und daher 18% plus. Heute eben andere Richtung. Wer hier investiert soll mit Totalverlust rechnen können

Und nu? Ergebnisse sollen ja diese Woche kommen. Nicht das da Insider verkaufen

Sieht nicht gut aus...

Freitag hatten wir knapp 17 Mio Volumen.

Nicht da, wenn Ergebnisse schlecht sind kannst mit >-60% rechnen. Leute wollen ihre Gewinne sichern, war vllt auch ne Bullenfalle aber bei 26k gehandelte Aktien NASDAQ ists egal.

Ergebnisse schlecht???Finde nix....

https://app.bpiq.com/catalyst-calendar

https://www.reddit.com/r/ATYR_Alpha/s/3E4KoVY6RB Sehr interessanter Beitrag zusammengefasste Notizen von Cantor Analyst und dem Kol Call Cantor Fitzgerald has reiterated its Buy (Overweight) rating on aTyr Pharma (ATYR) as of early September 2025, reflecting strong optimism ahead of key Phase 3 trial results for the company’s lead drug candidate, efzofitimod, in pulmonary sarcoidosis. The investment firm sees a substantial upside potential—if Phase 3 results are positive, Cantor projects the stock could rise to $15–$20 per share, representing a possible 200–300% gain from current levels. Conversely, a negative outcome could push ATYR below $1 per share, potentially an 80–90% downside. Key Points from Cantor Fitzgerald’s Rating • Cantor Fitzgerald’s analyst, Prakhar Agrawal, maintains the Buy rating, noting both substantial upside and significant risk centered on the pivotal EFZO-FIT Phase 3 study of efzofitimod. • The trial has been well executed, and management has reported observable separation in patient outcomes—even from blinded data—suggesting either drug activity or overuse of steroids in historical treatments. • Topline results from the Phase 3 trial are expected to be announced in early-to-mid September, with detailed data presentation scheduled for the European Respiratory Society conference later this month. Other Analyst Views and Context • H.C. Wainwright and Leerink Partners also reiterate bullish stances, with price targets as high as $35 (H.C. Wainwright) and $16 (Leerink), highlighting broader analyst confidence as the trial readout approaches. • ATYR has joined the Russell 2000 and 3000 indexes as of June 27, 2025, marking another milestone for the biotech. • The stock is highly volatile: up over 150% year-over-year but down nearly 24% in the most recent week, underscoring the “binary” near-term risk/reward based on upcoming data. Cantor Fitzgerald’s continued Buy call underscores strong expectations for positive Phase 3 results as a critical catalyst for ATYR’s next move